Search

CarrerasLeaders call two is now open

The second CarrerasLeaders call is open: apply now to the postdoctoral program to empower future leaders in the fight against blood cancers.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma

EHA and ESMO agreed to collaborate in the production of European Guidelines for different hematological malignancies. For the second workshop in the series participants joined us for the EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma.

Read more

Position of EHA on Clinical Trials

 

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Read more

EHA-SWG Scientific Meeting on Shaping the Future of Mesenchymal Stromal Cells Therapy

Dates: November 23-25, 2017
Location: Amsterdam, The Netherlands
Chair: WE Fibbe, F Dazzi

Organized by:

EHA and the EHA Scientific Working Group on Mesenchymal Stromal Cells

The SWG Meeting “Shaping the future of MSC therapy” brought together basic science, as well as translational and clinical research.…

Read more